No Detail Found!

A comparative study to assess safety and efficacy of vildagliptin and metformin with glimepiride and metformin among type 2 diabetes patients

Author(s)
Ibrar Ahmed Department of Endocrinology, MTI Lady Reading Hospital, Peshawar-Pakistan
Zafar Ali Department of Medicine, MTI Lady Reading Hospital, Peshawar-Pakistan
Muhammad Abdur Rahman Afridi Department of Medicine, MTI Lady Reading Hospital, Peshawar-Pakistan
Sobia Sabir Ali Department of Endocrinology, MTI Lady Reading Hospital, Peshawar-Pakistan
Mohammad Nawaz Department of Endocrinology, MTI Lady Reading Hospital, Peshawar-Pakistan
Tahir Ghaffar Department of Endocrinology, MTI Lady Reading Hospital, Peshawar-Pakistan
Abstract
Objective: To assess the safety and efficacy of Vildagliptin with metformin and Glimepiride with metformin among Type 2 Diabetes Mellitus (T2DM) patients with inadequate glycemic control using Metformin mono-therapy. Methodology: This comparative, interventional study was conducted at the Medicine and Endocrinology Depart­ment, Lady Reading Hospital, Peshawar. A total of 180 T2DM patients were divided into two groups (Glimepiri­de-Metformin group and Vildagliptin-Metformin group), with 90 patients in each group. Glycosylated hemoglobin (HbA1c), Fasting Plasma Glucose (FPG), Postprandial Glucose (PPG) were assessed with hypoglycemic incidences, weight gain, other adverse drug reactions were also monitored. The 1st follow-up visit was planned after 12-weeks of receiving the treatment and the 2nd after 24-weeks. Recorded data was analyzed through SPSS v.22.0. Results: The mean decrease in the FPG level after 24-weeks of treatment was -42.93±13.46 mg/dl in Vildaglip­tin-Metformin group, while it was. -46.76±11.04 mg/dl in the Glimepiride-Metformin group. Similarly, both drugs, Vildagliptin-Metformin vs Glimepiride-Metformin decreased mean PPG and HbA1c level i.e., -42.93 mg/dl vs. -46.76 mg/dl and -3.12% vs. -2.39% respectively (p<0.05). Mild adverse effects, like hypoglycemic incidences (10%) and weight gain (73.31±13.94 kg at 2nd visit) was more prominent among the Glimepiride-Metformin group. Conclusion: In terms of safety and efficacy, the Vildagliptin-Metformin combination showed a considerably health­ier response in achieving the HbA1c level among T2DM patients, with no weight gain and decreased risk of hypo­glycemia as compared to Glimepiride.
Publication Details
Page(s) 136-142
Published Journal: Journal of Postgraduate Medical Institute, Volume: 35, Issue: 3, Year: 2021

Request the full text from PASTIC

Keywords
Type 2 diabetes mellitus, Combination therapy, glimepiride, Vildagliptin, Metformin.
0

Citations

0

Downloads

87

Views